Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expression”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07631884
What this trial is testing

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

Who this might be right for
Solid TumorsNeoplasms (Cancer / Tumors)Advanced Malignant Solid Neoplasm+13 more
Haihua Yuan 15
Testing effectiveness (Phase 2)UnknownNCT02226757
What this trial is testing

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Who this might be right for
NSCLCHER2-expressionEGFR-mutation
Amsterdam UMC, location VUmc 16
Early research (Phase 1)Ended earlyNCT02512237
What this trial is testing

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Zhejiang Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Testing effectiveness (Phase 2)Ended earlyNCT02115048
What this trial is testing

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Who this might be right for
Breast Neoplasms
Translational Research in Oncology 44
Not applicableLooking for participantsNCT04660435
What this trial is testing

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

Who this might be right for
Metastatic Breast CancerER Positive Breast CancerHER2-negative Breast Cancer
Fondazione Sandro Pitigliani 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT06314997
What this trial is testing

Dynamic Changes in Circulating Tumour Cells Protein Expression

Who this might be right for
Objective Responsive Rate (ORR)
Matteo's Friends 150
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06630871
What this trial is testing

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Who this might be right for
NMIBC
Fujian Medical University Union Hospital 40
Very early researchStudy completedNCT04674722
What this trial is testing

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

Who this might be right for
Breast CancerRadiotoxicity
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 43
Not applicableLooking for participantsNCT07586215
What this trial is testing

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

Who this might be right for
Breast Cancer Metastatic
Fudan University 100
Testing effectiveness (Phase 2)UnknownNCT04818333
What this trial is testing

SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 157
Not applicableLooking for participantsNCT06916637
What this trial is testing

Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

Who this might be right for
Breast CancerBreast Cancer, HER2-Expression
The Affiliated Hospital of Qingdao University 40
Early research (Phase 1)Study completedNCT05203497
What this trial is testing

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2

Who this might be right for
Breast Cancer Female
Tomsk National Research Medical Center of the Russian Academy of Sciences 30
Not applicableStudy completedNCT02654444
What this trial is testing

Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue

Who this might be right for
Breast Cancer
Applied Spectral Imaging Ltd. 3
Not applicableStudy completedNCT01077648
What this trial is testing

Brain Metastasis in Breast Cancer Patients

Who this might be right for
Cancer
GlaxoSmithKline 1
Early research (Phase 1)UnknownNCT00367250
What this trial is testing

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Medical University of Vienna 32
Next Page